Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – Time to Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF) gapped down prior to trading on Tuesday . The stock had previously closed at $46.3750, but opened at $43.1050. Zealand Pharma A/S shares last traded at $43.1050, with a volume of 103 shares changing hands.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a report on Thursday, June 4th. Jefferies Financial Group cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Barclays cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 8th. Berenberg Bank downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Zealand Pharma A/S has a consensus rating of “Hold”.

Zealand Pharma A/S Stock Performance

The company has a fifty day simple moving average of $47.18 and a two-hundred day simple moving average of $46.30. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The company has a market cap of $3.08 billion, a PE ratio of 7.15 and a beta of 0.89.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. The company’s research programs address serious and underserved conditions, particularly metabolic diseases, gastrointestinal disorders and rare diseases. Zealand combines proprietary peptide technologies with drug-development expertise to create therapies designed to improve treatment outcomes and patient convenience.

Zealand’s commercial portfolio includes Zegalogue (dasiglucagon), an injectable treatment for severe hypoglycemia in people with diabetes.